Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study - Takeaways - MDSpire

Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study

  • By

  • Jun Fang

  • Siyi Zhong

  • Tielong Wang

  • Kang He

  • Aibo Mu

  • Meiching Ong

  • Yimou Lin

  • Zebin Zhu

  • Ning Wang

  • Jiancheng Wu

  • Zhihao Wang

  • Zhao Li

  • Feng Gao

  • Li Zhuang

  • Zhiyong Guo

  • Shusen Zheng

  • Hao Li

  • Shugeng Zhang

  • Qi Ling

  • June 1, 2026

  • 0 min

Share

  • 1

    Immune-related adverse events (irAEs) are significant predictors of allograft rejection in hepatocellular carcinoma patients treated with immune checkpoint inhibitors.

  • 2

    A predictive model incorporating irAEs, younger recipient age, and short washout periods demonstrates good discriminatory performance for rejection risk.

  • 3

    IrAEs indicate heightened immune activation, correlating with increased peripheral immune cells and elevated proinflammatory factors in affected patients.

  • 4

    Identifying irAEs as a biomarker may improve patient selection and risk stratification prior to liver transplantation.

  • 5

    Incorporating immune monitoring into transplant planning could enhance individualized washout intervals and immunosuppressive strategies.

Original Source(s)

Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study

  • by Jun Fang, Siyi Zhong, Tielong Wang, Kang He, Aibo Mu, Meiching Ong, Yimou Lin, Zebin Zhu, Ning Wang, Jiancheng Wu, Zhihao Wang, Zhao Li, Feng Gao, Li Zhuang, Zhiyong Guo, Shusen Zheng, Hao Li, Shugeng Zhang, Qi Ling

  • June 1, 2026

Related Content

Longitudinal changes in nutritional status during induction chemotherapy and their association with treatment outcomes in pediatric patients with newly diagnosed acute myeloid leukemia

Diagnosis and treatment of neurofibromatosis type 1 with malignant transformation and multiple gastrointestinal stromal tumors: a case report and literature review

Novel models for predicting individualized outcomes in patients with advanced hepatocellular carcinoma receiving immunotherapy